Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, is advancing its lead drug candidate Lucid-MS toward Phase 2 clinical trials for multiple sclerosis (MS). Lucid-MS is a patented, first-in-class non-immunomodulatory neuroprotective therapy designed to directly protect the myelin sheath, which is damaged in MS, unlike conventional treatments that primarily target the immune system. The company recently completed Phase 1 safety and tolerability studies, paving the way for the next stage of clinical development.
According to an editorial featured by BioMedWire, Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies, supported by over a decade of scientific research. Quantum BioPharma is also collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients, potentially providing a critical tool for monitoring treatment efficacy. The editorial also highlights developments across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN).
Quantum BioPharma's approach represents a potential paradigm shift in MS therapy. Current disease-modifying therapies for MS, such as those from Biogen and Roche, primarily work by modulating the immune system to reduce inflammation and attacks on myelin. However, Lucid-MS aims to directly protect and repair myelin, the fatty substance that insulates nerve fibers and is essential for proper nerve signal transmission. If successful, Lucid-MS could offer a new treatment option for patients who do not respond adequately to existing therapies or who experience significant side effects.
The company is a biopharmaceutical firm dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. In addition to its MS program, Quantum has developed UNBUZZD, a product for alcohol misuse, and retains ownership of 19.84% of Unbuzzd Wellness Inc., along with royalty payments from sales. The company's stock trades on both the NASDAQ and the Canadian Securities Exchange under the symbol QNTM.
For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/iZmx1.
